Adeno-Associated Virus (AAV) Vectors Manufacturing

What are the challenges and solutions?

All across the globe, AAVs are getting the attention of scientists and companies working in gene therapy, as they provide the right combination of characteristics that make them one of the most promising vector today. In 2021 only, the global gene therapy market was 4.1 billion USD, and AAV vector therapies made up more than 43% of that market value!

Designing and manufacturing AAV vectors is complex, and to be successful, certain challenges must be addressed. This implies monitoring and optimtizing production for a thorough quality control process, including reliable ongoing characterization of process intermediates and the final product.

Key features include:

• Overview and data on the gene therapy market
• Description of AAV vectors’ genomes and transfer
• Challenges associated with AAV vectors’ design and manufacturing
• Analytical methods for AAV vector quality control with a description of innovative no-wash AlphaLISA™ assays

For research use only. Not for use in diagnostic procedures.